Phaseolus vulgaris
Phaseolus vulgaris, commonly known as the common bean, is a plant species in the legume family (Fabaceae). It is native to the Americas but has been introduced around the world. The species is economically important as a major source of protein and micronutrients.
Taxonomy[edit]
The Phaseolus vulgaris species was first described by Carl Linnaeus in his 1753 work Species Plantarum. The genus name Phaseolus comes from the Latin for "little boat", referring to the shape of the pods. The species name vulgaris means "common".
Description[edit]
Phaseolus vulgaris is an annual plant. It can grow to 2m in height, and the plants have a growth habit ranging from bushy (determinate) to climbing (indeterminate). The leaves are alternate, green, and trifoliate with ovate leaflets. The flowers are small, white or purple, and self-fertile, leading to the production of the beans.
Cultivation and uses[edit]
The Phaseolus vulgaris is cultivated worldwide for its edible beans, which can be harvested and consumed green (known as "snap beans") or allowed to mature and dry on the plant (known as "dry beans"). The beans are a staple food in many cultures and are a key source of protein.
Health benefits[edit]
Beans from Phaseolus vulgaris are rich in fiber and protein, and a good source of vitamins and minerals. They have been associated with various health benefits, including reducing the risk of heart disease and colorectal cancer, and helping to manage diabetes.
See also[edit]
References[edit]
External links[edit]
-
Phaseolus vulgaris
-
Phaseolus vulgaris
-
Phaseolus vulgaris
-
Phaseolus vulgaris
-
Phaseolus vulgaris
-
Phaseolus vulgaris
-
Phaseolus vulgaris
-
Phaseolus vulgaris
-
Phaseolus vulgaris
-
Phaseolus vulgaris
-
Phaseolus vulgaris
-
Phaseolus vulgaris
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian